How patients are helping Scotland say yes to more medicines
This article was originally published in Scrip
The Scottish Medicines Consortium, Scotland's health technology assessment agency for new medicines, is saying yes to more and more drugs, and greater involvement of patients in the decision making process seems to be the reason why. The SMC's chief pharmacist Anne Lee spoke to Scrip about how patient views are affecting decisions, and the progress of the SMC's new Patient and Clinician Engagement (PACE) process, aimed at improving access to orphan and end-of-life treatments.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.